在Covid-19中Dipyridamole和腺协同途径:一种果汁或圣杯
Hayder M Al-Kuraishy1, Ali I Al-Gareeb1, Engy Elekhnawy2
1Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriyah University, Baghdad, 14132 Iraq.
The Egyptian journal of medical human genetics
|July 31, 2023
概括
迪皮里达摩尔 (DIP) 可能通过提高腺水平和抑制固酶来帮助管理COVID-19,从而有可能减少炎症和疾病严重程度. 需要进一步的临床试验来确认其治疗疗效.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 冠状病毒疾病2019 (COVID-19) 是由SARS-CoV-2引起的全球流行病.
- 严重的急性呼吸系统综合征-冠状病毒-2 (SARS-CoV-2) 感染可以引发严重的炎症,急性肺损伤和急性呼吸系统应急综合征.
- SARS-CoV-2 感染与腺路径的破坏有关,包括腺抑制和固酶激活.
研究的目的:
- 审查二皮里达摩尔 (DIP) 在COVID-19管理中的潜在治疗效果.
- 在SARS-CoV-2感染的背景下,阐明DIP对腺协同路径的影响.
- 评估DIP在缓解COVID-19相关炎症和并发症方面的潜力.
主要方法:
- 使用在线数据库和相关关键字进行系统的文献搜索.
- 关于二皮里达摩尔,腺素,化酶和COVID-19的现有研究的小审查.
- 对与SARS-CoV-2相关的二皮里达摩尔的拟议作用机制的分析.
主要成果:
- 迪皮里达摩尔 (DIP) 可能通过增强腺和抑制固酶来减轻COVID-19的结果.
- DIP表现出潜在的抗SARS-CoV-2,抗炎和抗血小板性质.
- 通过DIP增加细胞外腺可能会产生抗炎和免疫调节作用.
结论:
- 迪皮里达摩尔作为一种潜在的COVID-19管理治疗剂显示出希望.
- DIP的治疗效果可以通过直接或间接地通过调节腺能途径来实现.
- 需要进行广泛的随机临床试验,以验证二皮里达摩尔和腺胺调节剂在治疗COVID-19中的安全性和有效性.
关键词:
艾利·阿里 (ALI) 是一个名字.在ARDS中,我们使用ARDS.亚丁氨酸 (Adenosine) 是一种氨基酸.在NLRP3中,NLRP3是NLRP3中的一个.基化酶是一种基化酶.这就是SARS-CoV-2病毒.更多相关视频
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
11.1K
04:17Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
Published on: September 27, 2024
716
相关概念视频
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
876
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
876
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
772
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
772
01:30Adrenergic Agonists: Therapeutic Uses
842
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
842
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
565
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
565
01:26Heart Failure Drugs: Inotropic Agents
625
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
625
01:16Antianginal Drugs: Nitrates and β-Blockers
649
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
649